Whether Cemiplimab has successfully entered the medical insurance catalog and the latest policy on reimbursement ratios

Cemiplimab is a humanized anti-PD-1 monoclonal antibody, mainly used to treat patients with locally advanced or metastatic cutaneous squamous cell carcinoma and some other solid tumors. It blocks the PD-1 signaling pathway and restores the anti-tumor activity of T cells, thereby inhibiting tumor growth. In clinical application, cimepilimab is an immune checkpoint inhibitor with a similar mechanism to nivolumab, pembrolizumab and other drugs, but it shows unique efficacy in certain specific indications.

As of now, cimepril monoclonal generic drug has not yet been marketed in China, and therefore has not been included in the national medical insurance directory. Due to the lack of official marketing and medical insurance reimbursement policies, domestic patients are temporarily unable to obtain the drug through medical insurance, and the price information is also unclear. If patients need to use this drug, they mainly rely on overseas channels to import original drugs. However, due to factors such as exchange rates, transportation, and tariffs, the cost is high and unstable.

In overseas markets, cimepilimab is already available in the US and European versions of the original drug. The common specifications are 350mg/7mL (50mg/mL). Its price is relatively expensive, probably between RMB 40,000 and RMB 100,000 per box. Since there are currently no generic drugs of cimepilimab on the market, overseas patients mostly choose the original drug. The cost of clinical use and acquisition is high, which also limits its application in a wide range of people.

Overall, cimepilimab has not yet been included in medical insurance in China, and patients need to pay attention to its marketing dynamics and updates to medical insurance policies. Once it is marketed and included in medical insurance, part of the cost may be reimbursed in the future, reducing the economic burden of medication. In current clinical practice, the use of cimepilimab needs to be based on patient indications and accessibility, as well as high overseas procurement costs and drug acquisition channels, to ensure treatment continuity and safety.

Keyword tags: cimepilimab, PD-1 inhibitor, cutaneous squamous cell carcinoma, medical insurance, unlisted

Reference materials:https://en.wikipedia.org/wiki/Cemiplimab